Limits...
Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.

Li Y, Pan K, Liu LZ, Li YQ, Gu MF, Zhang H, Shen WX, Xia JC, Li JJ - PLoS ONE (2015)

Bottom Line: The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006).In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients.This study provides a basis for alternative therapeutic strategies for metastatic NPC.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

ABSTRACT
In this study, we investigated the efficacy of sequential cytokine-induced killer cell (CIK) immunotherapy with gemcitabine plus cisplatin (GC) regimen chemotherapy in metastatic nasopharyngeal carcinoma (NPC) patients. Between September 2006 and April 2010, 222 NPC patients with distant metastasis after radiotherapy completion were retrospectively analyzed: 112 patients received 4-6 cycles of GC chemotherapy at 4-week intervals, followed by at least 4 cycles of CIK immunotherapy at 2-week intervals (GC+CIK group); the remaining 110 patients received 4-6 cycles of GC chemotherapy alone (GC group). The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006). In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients. This study provides a basis for alternative therapeutic strategies for metastatic NPC.

No MeSH data available.


Related in: MedlinePlus

Study flow diagram.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476660&req=5

pone.0130620.g001: Study flow diagram.

Mentions: The study protocol was approved by the ethics committees of Sun Yat-sen University Cancer Center, The People’s Hospital of Guangdong Province and The People’s Hospital of Shenzhen. Treatments were conducted in accordance with the approved guidelines. All NPC patients received 4–6 cycles of GC chemotherapy. Patients with severe adverse events (n = 16) and progressive disease (PD) (n = 23) during GC chemotherapy were excluded, as undergoing GC chemotherapy was deemed to be inappropriate for them. Also excluded were 45 patients who received greater than 4–6 cycles of maintenance GC chemotherapy. The remaining 222 patients were included in further analysis. The GC+CIK group/Arm 1, consisted of 112 cases who received sequential CIK maintenance treatment (at least 4 cycles of autologous CIK transfusion in 2-week intervals). The control GC group/Arm 2 included 110 patients who refused any treatment including chemotherapy, immunotherapy, and radiotherapy. If PD was detected in patients in either group during follow up, patients then resorted to other treatment options that did not include GC chemotherapy or CIK infusion. The uniform study protocol based on GC chemotherapy and sequential CIK immunotherapy was approved by the respective institutional review boards of the three medical institutes. All of the patients provided their signed informed consent before receiving GC chemotherapy or CIK treatment. The flow diagram of this study is shown in Fig 1.


Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.

Li Y, Pan K, Liu LZ, Li YQ, Gu MF, Zhang H, Shen WX, Xia JC, Li JJ - PLoS ONE (2015)

Study flow diagram.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476660&req=5

pone.0130620.g001: Study flow diagram.
Mentions: The study protocol was approved by the ethics committees of Sun Yat-sen University Cancer Center, The People’s Hospital of Guangdong Province and The People’s Hospital of Shenzhen. Treatments were conducted in accordance with the approved guidelines. All NPC patients received 4–6 cycles of GC chemotherapy. Patients with severe adverse events (n = 16) and progressive disease (PD) (n = 23) during GC chemotherapy were excluded, as undergoing GC chemotherapy was deemed to be inappropriate for them. Also excluded were 45 patients who received greater than 4–6 cycles of maintenance GC chemotherapy. The remaining 222 patients were included in further analysis. The GC+CIK group/Arm 1, consisted of 112 cases who received sequential CIK maintenance treatment (at least 4 cycles of autologous CIK transfusion in 2-week intervals). The control GC group/Arm 2 included 110 patients who refused any treatment including chemotherapy, immunotherapy, and radiotherapy. If PD was detected in patients in either group during follow up, patients then resorted to other treatment options that did not include GC chemotherapy or CIK infusion. The uniform study protocol based on GC chemotherapy and sequential CIK immunotherapy was approved by the respective institutional review boards of the three medical institutes. All of the patients provided their signed informed consent before receiving GC chemotherapy or CIK treatment. The flow diagram of this study is shown in Fig 1.

Bottom Line: The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006).In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients.This study provides a basis for alternative therapeutic strategies for metastatic NPC.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

ABSTRACT
In this study, we investigated the efficacy of sequential cytokine-induced killer cell (CIK) immunotherapy with gemcitabine plus cisplatin (GC) regimen chemotherapy in metastatic nasopharyngeal carcinoma (NPC) patients. Between September 2006 and April 2010, 222 NPC patients with distant metastasis after radiotherapy completion were retrospectively analyzed: 112 patients received 4-6 cycles of GC chemotherapy at 4-week intervals, followed by at least 4 cycles of CIK immunotherapy at 2-week intervals (GC+CIK group); the remaining 110 patients received 4-6 cycles of GC chemotherapy alone (GC group). The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006). In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients. This study provides a basis for alternative therapeutic strategies for metastatic NPC.

No MeSH data available.


Related in: MedlinePlus